Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Adult
Humans
B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Lung
Lung Neoplasms
/ drug therapy
Pain
/ etiology
Patient Reported Outcome Measures
Platinum
/ therapeutic use
Quality of Life
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
cemiplimab
non-small cell lung cancer
patient-reported outcomes
quality of life
symptom burden
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
revised:
11
05
2022
received:
25
03
2022
accepted:
23
06
2022
pubmed:
30
10
2022
medline:
15
12
2022
entrez:
29
10
2022
Statut:
ppublish
Résumé
In the EMPOWER-Lung 1 trial (ClinicalTrials.gov, NCT03088540), cemiplimab conferred longer survival than platinum-doublet chemotherapy for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. Patient-reported outcomes were evaluated among trial participants. Adults with NSCLC and Eastern Cooperative Oncology Group performance status 0 to 1 were randomly assigned cemiplimab 350 mg every 3 weeks or platinum-doublet chemotherapy. At baseline and day 1 of each treatment cycle, patients were administered the European Organization for Research and Treatment of Cancer Quality of Life-Core 30 (QLQ-C30) and Lung Cancer Module (QLQ-LC13) questionnaires. Mixed-model repeated measures analysis estimated overall change from baseline for PD-L1 ≥50% and intention-to-treat populations. Kaplan-Meier analysis estimated time to definitive deterioration. In PD-L1 ≥50% patients (cemiplimab, n = 283; chemotherapy, n = 280), baseline QLQ-C30 and QLQ-LC13 scores showed moderate-to-high functioning and low symptom burden. Change from baseline favored cemiplimab on global health status/quality of life (GHS/QOL), functioning, and most symptom scales. Risk of definitive deterioration across functioning scales was reduced versus chemotherapy; hazard ratios were 0.48 (95% CI, 0.32-0.71) to 0.63 (95% CI, 0.41-0.96). Cemiplimab showed lower risk of definitive deterioration for disease-related (dyspnea, cough, pain in chest, pain in other body parts, fatigue) and treatment-related symptoms (peripheral neuropathy, alopecia, nausea/vomiting, appetite loss, constipation, diarrhea) (nominal p < .05). Results were similar in the intention-to-treat population. Results support cemiplimab for first-line therapy of advanced NSCLC from the patient's perspective. Improved survival is accompanied by improvements versus platinum-doublet chemotherapy in GHS/QOL and functioning and reduction in symptom burden.
Sections du résumé
BACKGROUND
In the EMPOWER-Lung 1 trial (ClinicalTrials.gov, NCT03088540), cemiplimab conferred longer survival than platinum-doublet chemotherapy for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. Patient-reported outcomes were evaluated among trial participants.
METHODS
Adults with NSCLC and Eastern Cooperative Oncology Group performance status 0 to 1 were randomly assigned cemiplimab 350 mg every 3 weeks or platinum-doublet chemotherapy. At baseline and day 1 of each treatment cycle, patients were administered the European Organization for Research and Treatment of Cancer Quality of Life-Core 30 (QLQ-C30) and Lung Cancer Module (QLQ-LC13) questionnaires. Mixed-model repeated measures analysis estimated overall change from baseline for PD-L1 ≥50% and intention-to-treat populations. Kaplan-Meier analysis estimated time to definitive deterioration.
RESULTS
In PD-L1 ≥50% patients (cemiplimab, n = 283; chemotherapy, n = 280), baseline QLQ-C30 and QLQ-LC13 scores showed moderate-to-high functioning and low symptom burden. Change from baseline favored cemiplimab on global health status/quality of life (GHS/QOL), functioning, and most symptom scales. Risk of definitive deterioration across functioning scales was reduced versus chemotherapy; hazard ratios were 0.48 (95% CI, 0.32-0.71) to 0.63 (95% CI, 0.41-0.96). Cemiplimab showed lower risk of definitive deterioration for disease-related (dyspnea, cough, pain in chest, pain in other body parts, fatigue) and treatment-related symptoms (peripheral neuropathy, alopecia, nausea/vomiting, appetite loss, constipation, diarrhea) (nominal p < .05). Results were similar in the intention-to-treat population.
CONCLUSIONS
Results support cemiplimab for first-line therapy of advanced NSCLC from the patient's perspective. Improved survival is accompanied by improvements versus platinum-doublet chemotherapy in GHS/QOL and functioning and reduction in symptom burden.
Identifiants
pubmed: 36308296
doi: 10.1002/cncr.34477
pmc: PMC10092585
doi:
Substances chimiques
B7-H1 Antigen
0
Platinum
49DFR088MY
cemiplimab
6QVL057INT
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Banques de données
ClinicalTrials.gov
['NCT03088540']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
118-129Informations de copyright
© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Cancer Med. 2020 Oct;9(20):7363-7374
pubmed: 32846465
Support Care Cancer. 2011 Nov;19(11):1753-60
pubmed: 20886240
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
Lancet Oncol. 2017 Dec;18(12):1600-1609
pubmed: 29129441
JCO Oncol Pract. 2020 Oct;16(10):e1151-e1160
pubmed: 32539654
Lung Cancer. 2013 Aug;81(2):288-93
pubmed: 23561304
J Thorac Dis. 2018 Feb;10(Suppl 3):S412-S421
pubmed: 29593887
Support Care Cancer. 2014 Jan;22(1):181-7
pubmed: 24026981
JAMA Oncol. 2017 Jun 1;3(6):738-739
pubmed: 27658006
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
J Thorac Oncol. 2013 Aug;8(8):997-1003
pubmed: 23787802
Cancer. 2023 Jan 1;129(1):118-129
pubmed: 36308296
J Pain Symptom Manage. 2015 Feb;49(2):192-202
pubmed: 24973624
JAMA Oncol. 2019 Apr 1;5(4):457-458
pubmed: 30653227
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Br J Cancer. 2014 May 13;110(10):2427-33
pubmed: 24743709
J Natl Cancer Inst. 2019 May 1;111(5):459-464
pubmed: 30561711
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Psychooncology. 2003 Oct-Nov;12(7):694-708
pubmed: 14502594
Eur J Cancer Care (Engl). 2012 Sep;21(5):614-22
pubmed: 22309434
Eur J Cancer. 1994;30A(5):635-42
pubmed: 8080679
Clin Cancer Res. 2016 Apr 1;22(7):1553-8
pubmed: 26758559
J Thorac Oncol. 2014 Sep;9(9):1243-8
pubmed: 25122420
Support Care Cancer. 2015 Dec;23(12):3455-63
pubmed: 25791391
Lancet. 2021 Feb 13;397(10274):592-604
pubmed: 33581821
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Qual Life Res. 2015 Jan;24(1):5-18
pubmed: 24277234